<b>The Safety Profiles of Biological Drugs for Rheumatoid Arthritis </b>
نویسندگان
چکیده
منابع مشابه
Safety of conventional drugs and biologic agents for Rheumatoid Arthritis.
While initial researches documented that Rheumatoid Arthritis (RA) patients who took biologic agents had decreased symptoms with those receiving traditional treatment, safety of the drugs remains a concern. The authors in this paper review the safety of the RA new therapeutic approach utilizing biological agents and compare it with the safety of conventional disease-modifying anti-rheumatic dru...
متن کاملdrd1-drd5 expression profiles in arthritis rheumatoid
objectives the cause of rheumatoid arthritis (ra) as a chronic inflammatory autoimmune disease is still unknown. it appears that both genetic and environmental factors play a role in its pathogenesis. recent studies reveal that in addition to the cns, immune cells synthesis neurotransmitters so that these catecholamines can regulate immune functions. the aim of this study is to evaluate the dop...
متن کاملInvestigative Drugs for Rheumatoid Arthritis: Novel Targets
The last 15 years has seen a revolution in the development of a drug therapy armamentarium for treating patients with rheumatoid arthritis (RA) [1]. Prior to that general practitioners and rheumatologists were relatively limited in the number of agents which had shown clinical efficacy in the treatment of RA patients. Besides the use of gold in some RA patients, non-steroidal anti-inflammatory ...
متن کاملCONCISE REPORT Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis
Background: The progression of rheumatoid arthritis (RA) can be retarded or halted by disease modifying antirheumatic drugs (DMARDs). Next to inefficacy, toxicity limits their use. Objective: To explore the toxicity profiles of DMARDs in daily life. Patients and methods: Five hundred and ninety three patients with RA charts (>2300 patient years of treatment) were reviewed at two rheumatology ou...
متن کاملToxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis.
BACKGROUND The progression of rheumatoid arthritis (RA) can be retarded or halted by disease modifying antirheumatic drugs (DMARDs). Next to inefficacy, toxicity limits their use. OBJECTIVE To explore the toxicity profiles of DMARDs in daily life. PATIENTS AND METHODS Five hundred and ninety three patients with RA charts (>2300 patient years of treatment) were reviewed at two rheumatology o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku
سال: 2017
ISSN: 1342-0445,1882-790X
DOI: 10.3820/jjpe.21.63